| Safeway Pharmacy #1123 | |
| 2249 Cascade Ave, Hood River, Oregon 97031 | |
| (541) 386-8374 |
| Name | Safeway Pharmacy #1123 |
|---|---|
| Organization Name | Safeway Inc |
| Location | 2249 Cascade Ave, Hood River, Oregon 97031 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (541) 386-8374 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Anthony-Samuel LaMantia, PhD, professor in the Department of Pharmacology and Physiology and Director of the GW Institute for Neuroscience in the School of Medicine and Health Sciences has been awarded a grant from the National Institutes of Health to identify molecular mechanisms that define embryonic olfactory epithelium (OE) stem cells.
Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.
The cause of the allergic reaction are T lymphocytes (T cells). These cells are part of the body's defences and normally react to viruses or bacteria in the skin.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
| NPI Number | 1194754143 |
| Organization Name | SAFEWAY INC |
| Doing Business As | SAFEWAY PHARMACY #1123 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2249 Cascade Ave, Hood River, OR 97031 |
| Phone Number | 541-386-8374 |
News Archive
Anthony-Samuel LaMantia, PhD, professor in the Department of Pharmacology and Physiology and Director of the GW Institute for Neuroscience in the School of Medicine and Health Sciences has been awarded a grant from the National Institutes of Health to identify molecular mechanisms that define embryonic olfactory epithelium (OE) stem cells.
Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.
The cause of the allergic reaction are T lymphocytes (T cells). These cells are part of the body's defences and normally react to viruses or bacteria in the skin.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
News Archive
Anthony-Samuel LaMantia, PhD, professor in the Department of Pharmacology and Physiology and Director of the GW Institute for Neuroscience in the School of Medicine and Health Sciences has been awarded a grant from the National Institutes of Health to identify molecular mechanisms that define embryonic olfactory epithelium (OE) stem cells.
Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.
The cause of the allergic reaction are T lymphocytes (T cells). These cells are part of the body's defences and normally react to viruses or bacteria in the skin.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
Indian Creek Family Eye Care Type: Medicare Supplier Location: 1700 12th St,, Hood River, Oregon 97031 Phone: (541) 386-1700 | |
Merriam Prosthetics Orthotics Type: Prosthetic/Orthotic Supplier Location: 1204 13th St, Hood River, Oregon 97031 Phone: (541) 386-4134 | |
Safeway Pharmacy #1123 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2249 Cascade Ave, Hood River, Oregon 97031 Phone: (541) 386-8374 | |
Rite Aid Pharmacy 05328 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2049 W Cascade Ave, Hood River, Oregon 97031 Phone: (541) 387-2428 | |
Walgreens #11696 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1727 12th St, Hood River, Oregon 97031 Phone: (541) 386-6280 |